FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bur	den									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Landen Jaren					2. Issuer Name and Ticker or Trading Symbol CASSAVA SCIENCES INC [SAVA]							5. Relationship of Reporting (Check all applicable) Director Officer (give title			g Pers	10% Ov	vner	
(Last) (First) (Middle) 6801 N CAPITAL OF TEXAS HWY, BLDG 1 SUITE 300				Date of Earliest Transaction (Month/Day/Year) 11/18/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)								below) below) Chief Clinical Dev. Officer 6. Individual or Joint/Group Filing (Check Applicable						
(Street) AUSTIN (City)			78731 (Zip)		4. IT AM	enament,	Date o	or Original F	-iled	(iviontn/Da	ıyı rear)		6. Ind Line)	Form fi	iled by One	e Repo	orting Perso	n
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transac Date Month/Da	Execution Date,		Code (li	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)				4 and Securitie Beneficia		s ally following	Form (D) o	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)		ice	Transact (Instr. 3 a	ction(s)			(11.501. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)			Cod	ransaction of ode (Instr. Derivative		Expiration Date of Securi (Month/Day/Year) Underlyii		urities lying tive Security		3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Cod	ie V	(A)		Date Exercisabl		xpiration ate	Title	Amor or Numl of Share	ber					
Stock Option (Right to Buy)	\$27.95	11/18/2024		A		85,000		(1)	1	1/18/2034	Common Stock	85,0	000	\$0	85,000	0	D	

Explanation of Responses:

1. The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025.

/s/ Eric J. Schoen by Power of Attorney

11/20/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.